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We conducted a prospective randomized multicenter clinical 
trial comparing the effects of granulocyte-macrophage col- 
ony-stimulating factor (GM-CSF) as an adjunct to intensive 
chemotherapy in patients of 61 years and older with un­
treated newly diagnosed acute myeloid leukemia (AML). Pa­
tients were randomized to either receive daunomycin-cyto- 
sine arabinoside with GM-CSF or daunomycin-cytosine 
arabinoside (control arm). Based on the rationale that GM- 
CSF might sensitize the leukemic cells to the cytotoxicity of 
chemotherapy as well as enhance white blood cell regenera­
tion, GM-CSF was given during chemotherapy as well as 
after chemotherapy. Patients were treated with one, and in 
case of a partial response, with two remission induction 
cycles. When a complete remission was attained they re­
ceived one additional cycle of consolidation therapy. Of 318 
evaluable patients with a median age of 68 years, 157 were 
randomized to receive GM-CSF and 161 were assigned to 
control therapy. The effect of GM-CSF on treatment was 
evaluated according to intention-to-treat. Complete remis­
sion was achieved in 56% of the patients in the GM-CSF 
group and 55% of the control patients (P = .98). Recovery 
of neutrophils was significantly faster in GM-CSF-treated
patients. The median time of recovery of neutrophils to­
wards 0.5 x 109/L was 23 days in the GM-CSF group versus 
25 days in the control group (P -  .0002) with the percentages 
of patients who recovered being 81% and 71%, respectively. 
With a median follow-up of 36 months, the probabilities of 
survival at 2 years after randomization were estimated at 
22% for individuals assigned to the GM-CSF treatment as 
well as for control patients (P =  .55). Disease-free survival 
at 2 years compared 15% and 19% for the two treatment 
groups (P — .69). The number of nights spent in the hospital, 
number of transfusions, and frequencies and types of hemor­
rhages and infections did not differ either. The cytogenetic 
results at diagnosis of this study in elderly AML shows that 
there is a relatively high numerical representation of patients 
with abnormal cytogenetics (55% of documented cases), 
who showed significantly inferior response rates and sur­
vival duration. We conclude that, except for a faster neutro­
phil recovery, GM-CSF during and after induction chemo­
therapy does not improve the clinical outcome of elderly 
patients with AML.
1997 by The American Society of Hematology.
.AlCUTE MYELOID LEUKEMIA (AML) is seen at all ages, but more than half of the patients with AML are 
60 years old or older.1,2 Intensified cytotoxic therapy and 
bone marrow transplantation have improved the prognosis 
of AML in recent years in young and middle-aged adults.3 
However, these modern approaches of therapy have, as yet, 
appeared of only little benefit to individuals with AML older 
than 60 years. The reasons for a lack of improvement of 
treatment outcome in the elderly probably relate to the fact 
that aged people have limited abilities to tolerate the toxicity 
associated with intensive chemotherapy. In addition, aged 
individuals suffer from AML which is a priori more resistant 
to chemotherapy.“1 Therefore, one may assume that any effort 
at improvement of the efficacy of treatment should be di­
rected at supporting the patients’ tolerances to chemotherapy 
or overcoming primary drug resistance in patients of greater 
age.
The results of a variety of studies, all conducted in patients 
with AML of 60 years of age or more, have indicated that 
these individuals have an approximately 50% probability of 
entering complete remission (CR).5'12 Approximately 30% 
of remission induction failures are caused by early death or 
death during the hypoplastic phase postchemotherapy, ie, 
mainly because of infections,4 The higher death rate would 
support the notion that elderly individuals are less able to 
tolerate the consequences of severe infections. Approxi­
mately 10% of these patients die during or within 1 week 
after completion of chemotherapy (early death) and 20% of
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DNR 30 mg/m2 day 1-3 
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DNR 30 mg/m2 day 1-3 
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s.c. 12 hrsfor 12 days 
(6 wk cycles)
Fig 1. Schema of study.
GM-CSF 5 ja.g/kg cont. i.v. day 0-28
(or until granulocytes 0.5x109/l ) -during 3 days
the patients expire during the subsequent postchemotherapy 
interval (hypoplastic death). Elderly patients who experience 
significant toxicity after the first cycle of chemotherapy are 
generally withdrawn from additional efforts of treatment. 
Thus, the obstacles to offer adequate therapy to older patients 
with AML are still considerable. There has been hope that 
the hematopoietic growth factors might hasten hematopoietic 
recovery and, thus, have a role in reducing the incidence 
and severity of complications and mortality.
Resistance of AML to chemotherapy has been the second 
major cause of treatment failure in patients aged 60 years 
or more. The proportion of patients showing primary resis­
tance to chemotherapy as the cause of remission induction 
failure is approximately 20% to 30%.4 Thus, primarily re­
fractory leukemia is another main determinant of unfavor­
able outcome. The hematopoietic growth factors have also 
received considerable interest because of their ability in vitro 
to enhance the killing of leukemic blasts or leukemic colony- 
forming cells by cytotoxic drugs. Exposure of leukemic cells 
to cytarabine in the context of growth factor stimulation has 
shown an increase in formation of cytarabine-triphosphate 
(Ara-CTP), increased DNA uptake of radiolabeled cytara­
bine in leukemic cells, and, in addition, enhancement of
m* intravenous bolus on days 1, 2, and 3) and cytarabine (200 mg 
per continuous infusion [c.i.]) on days 1 to 7 as induction therapy 
(control group) or the same chemotherapy for induction combined 
with GM-CSF. The comparison was not blinded. In case of a partial 
response to the induction cycle, patients were planned to receive a 
second identical course of treatment. Complete responders were to 
receive one cycle of consolidation therapy that consisted of the same 
therapy but with one day of daunomycin only. The choice of the 
daunomycin dose was 30 mg/m2, which is less than is usually used in 
young adults. A reduced daunomycin scheme had produced similar 
response rates in elderly patients. |1,,2° The main objective of the study 
was to evaluate the effects of GM-CSF on the response rate. In 
addition, the survival, disease-free survival (DFS), duration of post­
chemotherapy cytopenia, frequency of infectious complications, and 
number of days spent in the hospital during and after induction 
chemotherapy in these individuals were evaluated. After consolida­
tion patients were assigned according to a second randomization to 
receive either eight cycles of 12-day cytarabine (low dose) at 6- 
week. intervals or no maintenance chemotherapy.
Eligibility. Patients aged 61 years and more with newly diag­
nosed AML were eligible, including M0-M6 according to the 
French-American-British (FAB) classification.21"  Patients with sec­
ondary leukemias after previous chemotherapy or previous myelo­
dysplasia (MDS) were also included. Patients were not eligible if 
they had previously been treated for AML or MDS with ehemother-
cytotoxicity.,MH These in vitro observations have set the apy or hematopoietic growth factors, if they were refractory to plate-
stage for introducing hematopoietic growth factors in clinical 
protocols. It was argued that the simultaneous administration 
of hematopoietic growth factors in vivo with chemotherapy 
might prime the leukemie cells and render the cells more 
susceptible to cell killing by cytarabine in vivo.
Here the investigators present the results of a clinical ran­
domized phase III study in which granulocyte-macrophage 
colony-stimulating factor (GM-CSF) was applied concomi­
tantly with chemotherapy with the objective of enhancing 
chemotherapy efficacy. GM-CSF was also given after che­
motherapy to accelerate myeloid recovery and mitigate mor­
bidity and mortality.
MATERIALS AND METHODS
Study design. (Fig 1) Patients aged 61 years and older were 
entered after informed consent was given in a phase III study in 
which they were randomized to receive either daunomycin (30 mg/
let transfusion, or if (hey were in poor general condition with severe 
hepatic, cardiac, pulmonary, or renal disease.
GM-CSF trial drug. Molgrastim (Sandoz, Basel, Switzerland) 
is an Escherichia colt-derived GM-CSF. It was applied at 5 /tg/kg/ 
day c.i. starting at day 1 (1 day before the start of chemotherapy) 
and given during and after the chemotherapy until granulocyte recov­
ery of 0.5 X lO'VL (for 3 days) but not beyond day 28. As an 
alternative to the intravenous route, GM-CSF could be administered 
once daily subcutaneously, when the patients were discharged from 
the hospital at the end of the hypoplastic phase. In case of white 
blood cell counts (WBCs) of 30 X 10‘7L or more at diagnosis, the 
start of treatment with GM-CSF was postponed until WBCs had 
dropped during the first days of chemotherapy to less than 20 x 
lO'VL. If, during treatment, the WBCs would increase to 50 X 10'V 
L or more, GM-CSF was to be interrupted until the counts had 
declined to 20 x 10'VL. GM-CSF was discontinued in case of signs 
of progressive leukemia and in case of serious toxicity considered 
to be attributable to GM-CSF.
Criteria of response and evaluation of outcome. CR was defined
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by a nonnocellular bone marrow containing less than 5% blast cells 
including monocytoid cells, less than 10% blast cells and promyelo­
cytes, and less than 50% erythroid cells; no evidence of extramedul- 
lary leukemia; and recovery of peripheral blood values to platelet 
counts o f at least 100 X 10‘YL and polymorphonuclear neutrophils 
(PMNs) of at least 1.5 X 10‘7L. Partial remission (PR) was defined 
by bone marrow smears containing between 5.1% and 25% blasts 
and less than 5% circulating blast cells. Failures of response were 
classified as treatment resistance when there was no reduction of 
the leukemic cell infiltration in the marrow or a reduction that would 
not meet the criteria o f PR or CR. Hypoplasia followed by leukemic 
regrowth was also classified as resistant disease. Early death was 
defined as death before the completion o f the first cycle of induction 
therapy, and hypoplastic death was defined as death after the comple­
tion of induction cycle (1 or 2) before hematological recovery. Re­
lapse was defined as recurrence of leukemia after initial CR as 
documented by cytological or pathological evaluation of bone mar­
row or blood smears or pathological diagnosis of extra medullary 
leukemia. Standard cytogenetic techniques, including direct prepara­
tions, incubation of cells for 24 or 48 hours, and banding techniques 
were used23 at diagnosis to karyotype the leukemia. Normal (NN) 
cytogenetics (which included the deletion of the Y chromosome), 
abnormal cytogenetics (AA), and a mosaicism of abnormal and nor­
mal karyotypes (AN) were recorded. The NN score was applied only 
when a minimum number of 20 mitoses had been evaluated; in case 
of an examination of less metaphases, the analysis was considered 
inadequate.
Abnormalities 16q(22), t( 15 ; 17), and t(8; 21) were considered 
good risk abnormalities. NN karyotypes were classified as intermedi­
ate risk. Deletions of the long arm of chromosomes 5 and 7 (5q-, 
7q-X or the entire chromosomes (—5, —7) and all other specific 
cytogenetic abnormalities were considered poor risk abnormali-
Karyotypic abnormalities involving three chromosomes or 
more but without any of the specific poor risk or good risk aberra­
tions were designated as complex anomalies.
Maintenance chemotherapy. Patients, after consolidation and 
continuing in CR, were randomized between no further therapy (arm 
A) and low dose Ara-C chemotherapy (arm B). Arm B patients 
received cytosine arabinoside at 10 mg/m2 subcutaneously every 12 
hours on days 1 through 12 at 42-day intervals for a total of 8 cycles 
or until relapse.
Supportive care. All patients received prophylactic platelet 
transfusions when platelet counts dropped below 20 X 10‘YL. Red 
blood cells were usually transfused to maintain the hematocrit above 
30%. Daily fluid input and output were monitored. In case of a 
significantly positive fluid balance, or increase of body weight, di­
uretics (eg, furosemide) were applied, and in case of insufficient 
effect (increase of body weight of 3 kg or more) GM-CSF treatment 
was interrupted. Patients were put on prophylactic antibiotics and 
antifungal agents depending on the local recommendations of each
ties., 24,25
the difference was computed using the confidence interval analysis
(CIA) program.27
Overall survival was calculated from the date of first randomiza­
tion until date of death, whatever the reason. Patients still alive were 
considered as “ censored” observations at the date of last follow- 
up. The DFS was calculated for patients who achieved CR after 
induction from the date o f CR until the date o f first relapse or death 
in first CR. Patients who did not relapse or died were considered as 
censored observations at the date of last follow-up. Actuarial curves 
were computed according to the Kaplan-Meier technique.2'1 The stan­
dard error was calculated according to the Greenwood formula.2'1 
The difference between the curves according to the treatment groups 
was tested using the logrank lest.2'1 The prognostic significance of  
different initial variables was tested using the logrank test (for binary 
variables) or the logrank test for linear trend (for ordered variables). 
The relative risk (RR) of having an event per time unit in one 
treatment group versus another, along with its 95% Cl, was com­
puted by using the odds-ratio technique.27
The aim of the trial was to detect an increase of the CR rate from 
50% to 65% (alpha = 0.05, beta =  0.15) by adding the GM-CSF 
to the induction chemotherapy; the hope was that such an increase 
in the CR rate, if apparent, would lead to an increase in the survival 
at 2 years from 15% to 25%. Therefore, it was planned to enter 310 
patients, to evaluate their remission status after subsequent treatment 
steps (particularly after the induction course), and follow them until 
death. The final analysis was planned to be performed once 256 
deaths had been reported to see whether or not a significant differ­
ence in outcome would appear between both treatment groups (log-
rank test, alpha = 0.05, beta 0.20).
The time to platelet and PMN recovery after the first cycle of 
induction was calculated from the day of start of induction course
1 until the platelet count reached level 20 or 50 X 10‘VL and PMN 
count reached 0.5 or 1 X 10y/L, respectively. Only patients who 
recovered to reach these respective values were included in the 
statistical analysis. The same statistical ;s (Kaplan-Meier
and logrank test) were used to estimate and to compare the proportion 
of patients who recovered from the start o f induction cycle in the 
two treatment groups.
RESULTS
Response to treatment. The study was open for entry 
between November 1990 and October 1994, during which 
326 patients have been registered. Eight patients were con­
sidered ineligible or inevaluable. Reasons of ineligibility and 
inevaluability were poor physical condition (n = I), other 
malignant disease (n =  4), and incomplete data (n = 3). Of 
the 318 eligible and evaluable patients, 157 patients were 
randomized to chemotherapy with GM-CSF, and 161 pa­
tients were randomized to the control arm with no GM-CSF.
of the participating institutions, and in case of fever, broad spectrum Clinical and hematological characteristics of the patients are
antibiotics were initiated. The choice of antimicrobial agents was summarized in Table 1. The age ranged between 61 and 88
adjusted according to sensitivity data whenever a pathogen was iso- years, with a median value of 68 years in each of the two 
lated.
Statistical methods. Data were analyzed based on the intention 
to treat. The relationship between the initial categorized ordered 
variables (WBC, age, performance status, sex, de novo/secondary 
AML, FAB cytological type, and cytogenetics) and the CR rate was 
tested with the x 2 tesl; f°r linear trend. The usual test2'1 with the
correction for continuity was used to test the relationship between 
the treatment randomized and the CR evaluated after induction. The 
treatment difference of the incidence o f different types of screened 
toxicities observed during the induction period (d0-d28) was tested
using usual x ‘ tesl: (for binary toxicities) or the x" test for linear 
trend (for graded toxicities). The 95% confidence interval (Cl) o f
treatment groups. The proportion of patients with a poor 
pretreatment performance was slightly but not significantly 
greater in the GM-CSF group (Table 1 ).
CR after one or two cycles o f induction chemotherapy 
was achieved in 5 5 %  of patients in the control group and in 
56% of patients of the GM-CSF group (P = .98). Most of 
these individuals attained CR after the induction cycle I 
(Table 2). Reasons for not attaining CR were related to resis-
apy, prolonged hypoplasia, death in hypo­
plasia, and early death (Table 2).
tance to
Overall sunn and DFS. Patients have
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Table 1. Patient Characteristics Table 2. Response of AML to Induction Chemotherapy
Control
Group
<%)
GM-CSF
Group
(%>
Sex
Male 52 56
Age
61-69 64 58
70-79 33 39
Sr80 3 3
WBC*
<30 72 70
30-99 21 20oox—S
ii 7 10
FAB cytology
M0 6 4
M1 21 23
M2 36 35
M3 2 1
M4 11 12
M5 19 17
M6 2 4
Unknown 3 3
Cytogeneticst
Normal karyotype 22 32
Good risk abnormality 3 2
Intermediate risk abnormality 21 19
Poor risk abnormality 12 11
Failure of analysis/not done 42 36
Performance statust
Normal (0) 32 31
Ambulatory (1) 49 43
Bed ridden less than 50% of time (2) 16 22
Bed ridden & 50% (3) 2 5
AML
Secondary 22 22
De novo 78 78
Total 161 157
Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulat- 
ing factor; WBC, white blood cell count; FAB, French-American-British 
Classification; AML, acute myeloid leukemia.
*  x  10B/L .
t  Cytogenetic categories as defined in Materials and Methods. Com­
plex chromosome abnormalities were apparent in 4 patients of the 
control arm and 3 patients of the GM-CSF arm (ie, 8% of evaluated 
cases).
♦ The comparison of the differences in performance status between 
the two treatment groups (performance status grade 0 v 1 v ïs2) gives 
a P value of .23 (v2 test for linear trend).
for a median of 36 months after diagnosis. Probabilities of 
overall survival at 2 years after randomization were identical, 
ie, 22% (standard error [SE] =  3.5%) in the GM-CSF and
the control groups (P =  .55; Fig 2), and the RR estimate
was 0.93 (95% Cl [0.73; 1. . Of the 177 complete
responders to chemotherapy 11 patients died in first CR (5 
patients in the GM-CSF group and 6 patients in the control 
group). All other causes o f  death after CR were related to 
recurrence of leukemia. The death rates in the two arms were 
similar: 67 of 89 (GM-CSF) versus 61 o f 88 (no GM-CSF). 
DFS probabilities at 2 years after randomization were esti­
mated at 14% (SE =  4.1%) in the GM-CSF group and 19% 
= 4.3%0 in the control arm (P =  .69; Fig 3), and the
Control Group GM-CSF Group
Total 161 (100%) 157 (100%)
Complete response
After remission induction
cycle I 73 (45) 79 (50)
After remission induction
cycle I/ll 89 (55) 88 (56)
No complete response
Early death 5 (3) 0 (0)
Death in hypoplasia 16 (10) 22 (H)
Resistance to chemotherapy 51 (32) 47 (30)
Abbreviations: AML, acute myeloid leukemia; GM-CSF, granulo­
cyte-macrophage colony-stimulating factor.
RR estimate was 0.94 (95% C f  = [0.68; 1.30]). If all patients 
randomized are considered (including ineligible and non- 
evaluable cases), the treatment comparison remained practi­
cally the same.
GM-CSF treatment, hematopoietic recovery, and hospital­
ization. The patients in the GM-CSF group received GM- 
CSF during an average of 18 days (median, 20; range, 0- 
46). GM-CSF administration started on day 0 in 69% of the 
patients. In 21.5% of the patients the GM-CSF administra­
tion began between 1 and 4 days after the start of the chemo­
therapy, in 7.4% between 4 and 6 days, and in 2.5% with a 
delay of more than 6 days after commencing chemotherapy. 
This was generally because o f a leucocytosis of 30 X  10'V 
L or more because the protocol required GM-CSF to be 
postponed in that case. In a majority of the patients GM- 
CSF therapy was stopped prematurely, mainly because of 
possible toxicity o f GM-CSF. The reasons for discontinua­
tion of GM-CSF treatment, except for early PMN recovery 
(28 cases), were related to reappearance of blasts in the blood 
(8 cases), doubling of circulating blast counts (4 cases), and 
toxicity (63 cases). Figure 4 presents the time of recovery 
of PMNs towards 0.5 X  10‘7L. Median times to neutrophil
n  o
NumluM' ol pullcius «I risk
I M
157
M
fiV 2H
K
y
No CÎM
ciM-rsr
Fig 2. Duration of overall survival of patients randomized to che­
motherapy with or without GM-CSF (results based on an intention* 
to-treat analysis). N, number of patients in each group; O, observed 
number of deaths.
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Fig 3. DFS from CR of patients randomized to chemotherapy with 
or without GM-CSF. N, number of patients; O, observed number of 
relapses/deaths.
recovery o f 0.5 X  10‘7L after induction cycle I in GM-CSF 
treated patients and control patients were 23 and 25 days, 
respectively (P =  .0002). In addition, the proportion of pa­
tients who recovered to PMN of 0.5 X  109/L was greater in 
the GM-CSF group than in the control group: 81% (127/ 
157) versus 71% (115/161). The median times of recovery 
to a platelet value of 20 X  109/L in the GM-CSF and control 
groups were identical, ie, 22 days. The median (range) num­
ber of days spent in the hospital during induction cycle I 
were 32.5 days (range, 3 to 75) in the GM-CSF group and
32.0 days (range, 11 to 98) in the controls (P .87).
Prognostic factors for response and survival. The prog­
nostic impact o f WBC, age, sex, performance status, FAB 
classification, de novo AML versus secondary AML, and 
cytogenetics at diagnosis with regard to treatment outcome 
were assessed. There was no apparent relationship between 
age, sex, or FAB type and response or survival. Patients with 
a WBC of 100 X 10l)/L or more (n = 27), a poor performance 
status, and abnormal cytogenetics (AA and AN) showed a
Number of patients m  risk :
115
127
112 
124
A l
21
12
A
K
1
6
I)
No OM 
UM CSF
Fig 4. Time to neutrophil recovery towards 0.5 x 109/Lfor patients
Table 3. Prognostic Factors of Patients With AML for Response to
Remission Induction Treatment
Number of 
Patients
CR Rate 
(%) P Value
WBC
<30 226 58 .019*
30-99 65 57
2=100 27 30
Age
61-69 yrs 194 56 .83*
70-79 yrs 115 56
^80 yrs 9 44
Performance (WHO)
0 100 66
1 146 54 .008*
2 60 43
3 12 50
AML
De novo 248 56 .96t
Secondary 69 55
Cytogenetics*
NN 87 65 .041*
AN-AA 107 50
Good risk 8 75 .008*
Intermediate risk 63 54
Poor risk 36 36
Abbreviations: AML, acute myeloid leukemia; CR, complete remis­
sion; WBC, white blood cell count; WHO, World Health Organization; 
NN, normal; AN, abnormal and normal; AA, abnormal.
* x2 test for linear trend.
t  x2 test.
t  Cytogenetics was not done or reported or was not successful in 
124 patients (CR rate in this group was 54%). Complex chromosome 
abnormalities were shown in 17 patients of whom 57% attained CR. 
NN, AA, AN, good risk, intermediate risk, or poor risk categories as 
defined in Materials and Methods.
significantly reduced probability of attaining a CR (Table 
3). Specific cytogenetic abnormalities of favorable risk fie,
abn( 16), t(8;21), t(15; 17)] were present in 8 patients (ie, 4% 
of examined cases) only. Unfavorable type abnormalities 
( -5 ,  5q-, - 7 ,  7q-, complex, or other cytogenetic abnormali­
ties) were shown in 36 patients (19% of examined cases) 
and intermediate risk type abnormalities in 63 patients (ie, 
32% of examined cases). Among the subsets with cytogenet­
ics of unfavorable and intermediate risk the CR probabilities 
were 36% and 54%, respectively (P ~  .008). Finally, of the 
above listed factors, abnormal cytogenetics (Fig 5A; P <  
.001) and poor risk cytogenetic abnormalities (P <  .001), 
correlated with significantly shorter overall survival. Abnor­
mal karyotype (AA and AN; Fig 5B; P <  .007) and poor 
risk karyotypes also predicted for inferior DFS probabilities 
(P = .009).
Fever. The median duration of (ever (Fig 5) in associa­
tion with induction cycle I was 10.0 days in the GM-CSF 
arm (range, 0 to 40) and 6.0 days in controls (range, 0 to
41 ; P <*. 0 0 1 ) . 
live care. i patients in
ceived antibiotic treatment for fever or infections during a
randomized to induction therapy with or without GM-CSF. Y-axis median of 20 days (range, 0 to 40). In patients assigned to 
shows percentages of patients with PMN less than 0.5 x 10®/L. the control, arm antibiotics were administered during a me-
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Number o f  puticnis at r isk :
57
53
50
33
27
16
16
9
9
4
7
t
6
I
6
1
2 NN
A N - A A
Fig 5. Probability of overall survival and DFS in relation to cytoge­
netics. (A) Survival in relation to NN {normal karyotype) and AN-AA 
(abnormal karyotype). (B) DFS in relation to NN and AN-AA.
dian of 16 days (range, 0 to 80). Both patients in the control 
and GM-CSF groups received a median number of 12 plate­
let transfusions (range, 0 to 100). The median number of red 
blood cell transfusions given to either the GM -CSF- and 
control-treated patients did not differ significantly: 14 (range 
2 to 48) versus 12 (range, 2 to 40).
Toxicity. The frequencies o f hemorrhages, liver abnor­
malities, oral toxicity, nausea, cardiac rhythm abnormalities, 
neurotoxicity, bone pain, phlebitis, and infections were simi­
lar in both groups. However, the patients in the GM-CSI 
group experienced more diarrhea, renal abnormalities, fever, 
cutaneous toxicity, hypotension, fluid retention, and chills. 
Table 4 shows the frequencies o f  the latter complications 
during induction cycle I in each treatment group.
Maintenance treatment. Of 177 complete responders, a 
total of 88 patients were randomized, 44 patients per arm. 
The other patients refused to receive further therapy or 
showed early relapse. Two patients were ineligible, so that 
44 patients on arm A (no maintenance) and 42 patients on 
arm B (low-dose Ara-C) were evaluated with a median fol­
low-up of 2 years. DFS (from the time of second randomiza­
tion) at 2 years was estimated at 19% (SE «  6.3%) in arm 
A and 20% (SE = 6.9%) for arm B. There were no differ­
ences in the frequencies or types of relapse (bone marrow,
central nervous system, or extramedullary) nor in DFS and 
overall survival between patients on arm A or B maintenance
(Fig 6).
DISCUSSION
This randomized study considered the role of GM-CSF 
as an adjunct to chemotherapy in elderly patients with AML. 
Based on in vitro data, it was hypothesized that GM-CSF 
might improve the response of AML to cytotoxic therapy 
by combining chemotherapy with GM-CSF stimulation.I V IK 
It also was assumed that GM-CSF might possibly reduce 
the duration of leucopenia after chemotherapy and thereby 
also reduce the frequencies of bacterial and fungal infections 
and decrease morbidity or mortality. The results o f the study 
reported here show that treatment with daun.omycin-cytos.ine 
arabinoside combined with GM-CSF does not result in better 
response rates or longer survival of patients with AML of 
61 years and older. The percentages o f patients who attained
CR after induction treatment in the GM-CSF and the control
i
treated patients were similar. Thus, apparently the coadmin­
istration of GM-CSF with chemotherapy does not increase 
chemosensitivity to any measurable extent as a consequence 
of AML cell “ sensitization.” The use of GM-CSF postche­
motherapy did not prevent the complications during the hy-
Table 4. Relative Frequency {%) of Complications
During Induction Cycle I
Control
Group
GM-CSF
Group
Hemorrhage
Only petechiae 21 26
Other bleedings 26 25
Liver
Mild-moderate (1.25-5 x  normal) 31 37
Severe (a 5 x normal) 11 10
Oral
Erythema 17 14
Ulcers and other toxicity 7 12
Nausea/vomiting 30/35 32/34
Diarrhea*
Less than 2 days 23 23
More severe 18 30
Renal*
Mlld-modorate (1.26-5 x normal) 21 31
Severe (:-5 x normal) 3 3
Fever*
Subfebrile (<38"C) 12 11
a  38°’C 71 81
Cutaneous*
Erythema/desquamation/papules etc 43 55
Cardiac rhythm 22 22
Neurotoxicity 11 12
Bone pain 6 8
Hypotensiont 13 26
Fluid retention* 56 71
Chills* 18 37
Phlebitis* 8 17
Infection 77 78
* P < .05. 
t  P <  .01.
$ P <  .001.
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Fig 6. Outcome according to maintenance treatment randomized: 
no cytarabine versus low-dose cytarabine. (A) Overall survival and 
(B) DFS.
poplastic phase to any significant extent either. As a result, 
morbidity or mortality were not reduced. Why did the addi­
tion of GM-CSF to induction chemotherapy not produce any 
significant benefit? There may be various reasons to explain 
the lack of clinical efficacy of GM-CSF in the context of 
chemotherapy in patients with AML at higher age. The re­
sults were analyzed according to inten tion-to-treat. Many
cases). Thus, the analysis according to actual treatment, in­
stead of the intention-to-treat approach, did not show any 
differences either. Hence, it is unlikely that the withdrawals 
would have compromised any possible advantage of GM- 
CSF treatment. Why did the use of GM-CSF fail to improve 
treatment outcome? First, the 2-day reduction of duration of 
neutropenia may not have been significant enough to modify 
the death rate, especially because the neutrophil effect comes 
late when mucosal damage is no longer at its maximum. A 
second possible explanation for a lack of a measurable bene­
fit of GM-CSF might relate to the fact that in vivo dosaging 
of GM-CSF for sensitizing the AML cells to the cytotoxic 
effects of chemotherapy was suboptimal. The toxicity profile 
of GM-CSF treatment would suggest that higher dosages of 
GM-CSF cannot realistically be applied to patients of this 
age category. GM-CSF is assumed to mainly enhance cyto­
toxicity of the chemotherapeutic agent cytarabine through 
cell cycle activation. Thirdly, besides the GM-CSF dose, we 
cannot exclude the possibility that daunomycin, also in­
cluded in the chemotherapy regimen, counteracted cell cycle 
activation by GM-CSF and precluded a therapeutic effect of 
GM-CSF at this point. We did not examine, and, therefore, 
cannot be certain, that recruitment of the AML blasts to the 
active phase of the cell cycle after the administration of GM- 
CSF was truly achieved in vivo. A fourth explanation for 
the inability to extrapolate the in vitro efficacy of GM-CSF 
to an in vivo success might relate to the endpoints considered 
in vitro. The in vitro colony-forming cells might not be 
representative of the in vivo leukemia repopulating progeni­
tor cells, and, therefore, the in vitro data of chemotherapy 
priming may not at all predict for better efficacy in vivo.:x 
A possible stimulation of residual leukemic cells by postche­
motherapy as suggested by a recent European Organisation 
for the Research and Treatment o f Cancer (EORTC) random­
ized trial in younger AML patients,**’ counteracting an even­
tual priming effect of the prechemotherapy administration, 
is not probable because we did not document in the present 
study an overt leukemic regrowth stimulated by GM-CSF. 
Finally, other types of drug resistance (eg, multidrug resis­
tance to daunomycin) rather than resistance to cytarabine 
might be considered as predominant causes of failure in 
elderly patients with AM L”' so that GM-CSF priming would 
be less likely to modify chemotherapy responsiveness. What­
ever the reason, other strategies would need to be explored
patients, because o f possible toxicity related to GM-CSF enhance the efficacy o f chemotherapy with the aim of
treatment, discontinued GM-CSF treatment, so that in prac- mcreasing rate ( “ percentage remission” ) and
tice more than 40% of the patients allocated to the GM-CSF remission duration ( “ quality o f remission” ). Clearly, GM- 
arm of the study could not receive the intended dose or CSF does not offer a solution to the problem that approxi- 
schedule o f GM-CSF. However, an analysis based on actual mately 40% of patients with AML at a higher age still do 
application of GM-CSF treatment (instead of intention-to- 
treat) would not be appropriate. It would on one hand ex-
not res to
It is of note that patients with good risk cytogenetic fea- 
clude good cases with early PMN recovery (n =  28) but tures represent only a minima] fraction of patients with AML 
on the other hand exclude poor risk cases with progressive at a high age. The results of retrospective studies had pre­
leukemia on GM-CSF treatment (n = 12). To avoid such viously suggested that AMLs with favorable cytogenetics
defavoring and favoring effects, an analysis based on the 
actual application of GM-CSF treatment might be done ex-
are comparatively under-represented among patients of over 
60 years of age.10,11 The results of the prospective analysis
eluding early discontinuation because o f toxicity only. The of this study confirm the prognostic impact of the quantita- 
latter comparison yielded identical CR rates for control treat- tive over-representation o f poor-risk types AML in elderly 
ment (CR =  55.3%; n =  161 cases) and actual GM-CSF subjects. NN cytogenetics were scored according to a strict
criterion of a minimum of 20 evaluated metaphases. As manytreatment (CR = 55.3%; n 94 actual GM-CSF-treat
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as 55% of evaluable patients had chromosome abnormalities 
and only 3% presented with favorable cytogenetics. Thus, it 
is conceivable that the majority of these patients have an 
intrinsically unfavorable type of disease, so that any effort 
at improving outcome of this category of patients is compar­
atively unlikely to meet success. In fact, both CR rates and 
survival probabilities in patients with chromosome abnor­
malities or unfavorable types of cytogenetic abnormalities 
were significantly less as compared with those in elderly 
patients who have AML with normal cytogenetics.
The intervals towards neutrophil recovery of 0.5 X 10° 
and 1.0 X 107L (not shown) were significantly shorter in 
the GM-CSF treatment arm. In contrast, times of platelet 
recovery to 20 X 107L and 50 X 10‘VL did not differ signifi­
cantly between the treatment groups. Although there was 
an advantage for GM-CSF-treated patients regarding more 
rapid neutrophil recovery after chemotherapy, this difference 
did not result in fewer infections, shorter hospitalization, or 
a reduced morbidity or mortality. Apparently the quantitative 
benefit with regard to neutrophil recovery comes too late or 
is too small to be clinically meaningful.
Moderate to severe toxicities were seen more frequently 
in patients treated with GM-CSF. Adverse events reported 
were diarrhea, renal abnormalities, fever, cutaneous abnor-
study), but only after completion of chemotherapy. The days 
of hospitalization of the patients or the incidence of bacterial 
or fungal infections were not modified in any of the studies 
as a result of growth factor therapy. Survival did not improve
in patients on either G-CSF or GM-CSF treatment. In only 
one study36 was GM-CSF therapy associated with a better 
median survival; but the CR rate did not improve, and pla- 
cebo-treated controls showed an exceptionally poor survival 
(ie, median of 4.8 months), which is worse than is usually 
seen. It may also be noted that the latter study used a glyco­
sylated GM-CSF preparation and included patients between 
55 and 70 years and, thus, considered a population of a
eompan • age.16
Low-dose cytarabine postremission was evaluated by ran­
domization in approximately half of the patients with a com­
plete response but did not result in better overall survival or 
DFS. Because the second randomization was done in only 
88 cases, the statistical power of the latter analysis was lim­
ited. In another study in elderly AML patients, the use of 
a similar schedule of low-dose Ara-C improved the DFS 
significance.37 However, it should be noted that in that partie- 
ular study a less intensive dose of cytarabine (100 mg/m* 
every day) was employed, which may have conditioned for 
an additional benefit of low-dose Ara-C as maintenance
malities, hypotension, fluid retention, and chills. Patients on treatment. Here we employed 200 mg/m2 cytarabine during
GM-CSF experienced more days of fever than did control 
patients. These toxicities were considerable, and most of 
these were based on objective measurements. Therefore, al­
though the study was not double blinded, they were most 
likely to be attributed to the GM-CSF treatment. Early phase 
I and II studies with GM-CSF and granulocyte colony-stimu­
lating factor (G-CSF) given after completion of chemother­
apy in patients with AML did not provide indications of 
inhibition of leukemia clearance, stimulation of leukemic 
outgrowth, or recurrence of leukemia,'2 '4 although in vitro 
data had indicated that these cytokines might activate AML 
cell proliferation in culture.35 This had created caution for 
negative effects o f  growth factor treatment. This study and 
two previous randomized studies in elderly subjects have 
dealt with the use of GM-CSF after chemotherapy.11'0
induction, which might have eliminated any possible added 
advantage o f low-dose cytarabine.
In summary, based on the results of the study reported
inhere, we conclude that daunomycin-cytosine an 
adjunct with GM-CSF coadministered with and after chemo­
therapy is not an effective treatment strategy compared with 
daunomycin-cytosine arabinoside alone.
APPENDIX
Participating investigators institutions: B. Löwen-
other phase III study in patients o f higher age has explored 
a potential role o f  G-CSF.1“ In our study and three1 u2-,(1 other 
prospectively controlled studies, an enhanced regeneration 
of neutrophils was apparent. A reduction of the length of 
neutropenia by 2 to 7 days was seen in G-CSF- or
CSF-trei patients. ;r, the reduction of the dura­
tion of neutropenia was not associated with a decrease of 
the death rate in any of these studies. In one study1“
complete response rate improved significantly as a result of 
growth factor treatment after chemotherapy. The latter study 
differed in that G-CSF was employed. Why the complete 
response rate was better in only two of the four studies 
remains unexplained at the present time. In fact, the mortality 
rates were not different and in only one of the studies a 
reduction of the percentage o f resistant leukemia was re­
ported,12 which would have contributed to a greater response 
probability in case of G-CSF therapy. It is o f note that, in 
none of the previous studies was the hematopoietic growth 
factor applied concurrently with the chemotherapy with the 
objective of chemotherapy priming (as was done in our
berg (Daniel den Hoed Cancer Center, Rotterdam, The Neth­
erlands); E. Archimbaud (Hôpital Edouard Herriot, Lyon, 
France); G. Ossenkoppele (Free University Hospital, Am­
sterdam, The Netherlands); G.E.G. Verhoef and M.A. Boo- 
gaerts (University Hospital, Leuven, Belgium); E. Vellenga 
(University Hospital, Groningen, The Netherlands); P. Wij- 
ermans (Leyenburg Hospital, The Hague, The Netherlands); 
Z. Berneman (University Hospital, Antwerpen, Belgium); 
A.W. Dekker (University Hospital, Utrecht, The Nether­
lands); P. Sonneveld (University Hospital, Rotterdam, The 
Netherlands); P. Stryckmans (Institut Bordet, Brussels, Bel­
gium); P. Mims and Th. de Witte (University Hospital, Nij­
megen, The Netherlands); U. John (Klinikum Groszhadern, 
Ludwig University, Munich, Germany); H. Schouten (Uni­
versity Hospital, Maastricht, The Netherlands); R. Willemze 
(University Hospital, Leiden, The Netherlands); R. Zittoun 
(Hôpital Hôtel Dieu, Paris, France); J. van der Lelie (Univer­
sity Hospital, Amsterdam, T ■lands); D.
(University Hospital St. Jan, Brugge, Belgium); I. Sousa 
(Institute of Oncology, Coimbra, Portugal); M. Hayat
tut Gustave Roussy, Villejuif, France); W. Foremans (Uni­
versity Hospital Erasme, Brussels, Belgium); G. Fillet (CHU, 
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